Clinical Trial Update: Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PF-05221304 in subjects with varying degrees of hepatic impairment has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment

Drugs mentioned

• PF-05221304

Snippet

Sponsor: Pfizer | Conditions: Hepatic Impairment | Phase 1 | Status: COMPLETED | Results posted: 2019-08-08